The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Detailed Description
-----------------
Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB injury often occurs in the early stage of ischemic stroke, leading brain tissue edema or even hemorrhagic transformation with the development of ischemic injury. The biomarker of BBB damage, such as the level of serum occludin, can reflect the extent of BBB injury. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Official Title
-----------------
The Level of Blood Brain Barrier Damage Biomarker Predicting Hemorrhagic Transformation Following Acute Ischemic Stroke

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Diagnostic Test: the level of biomarker in bood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled patients aged 18-80years. Acute ischemic stroke Informed consent obtained. Exclusion Criteria: Tumor stroke or hemorrhagic stroke or hemorrhagic cerebral infarction on admission. Stroke or serious head trauma within the previous 3 months inflammatory or infectious diseases, cancer, coagulation disturbance disease and severe renal and liver failure blood sample occurred hemolysis or cloudy. Incomplete clinical data Platelet count of less than 100,000 per cubic millimeter Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds Pregnant or breast-feeding women Patients being enrolled or having been enrolled in other clinical trial -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change of serum biomarkers within 72h in ischemic stroke patients | The level of biomarkers are detected using Elisa(Enzyme Linked Immunosorbent Assay)，biomarkers including Occludin(ng/mL), Claudin-5(ng/mL), MMP-2/9(ng/mL)，c-Fn(ug/mL), ZO-1(pg/mL), vWF(ng/mL), IL-2RA(ng/mL), CCL16(ng/mL), CNTN(ng/mL), SELE(ng/mL) and PGLYRP1(ng/mL). | Day 0, Day 1, Day 2, Day 3. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood brain barrier, hemorrhagic transformation, ischemic stroke